Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

study. Relapse rates between these two arms also were not significantly different (32.7 percent (16/49) vs. 47.1 percent (32/68), respectively) and adverse events were similar among treatment groups (secondary endpoints). Early discontinuation rates were higher in the 72-week arm compared to the 48-week arm (23.3 percent (17/73) vs. 9.3 percent (8/86), respectively).

Reduced Dose and Duration of Peginterferon Alfa-2b + Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (REDD 2/3 Trial)(4)

Shorter duration treatment of patients chronically infected with HCV genotype 2 or 3 (G2/3) with peginterferon and ribavirin has been largely unsuccessful compared with standard-duration treatment (24 weeks). The implications of a reduced peginterferon dose in G2/3 patients were unknown. The primary objective of the REDD 2/3 study was to evaluate the effect of reduced treatment duration or a reduced PEGINTRON dose on SVR and relapse rates among treatment-naive G2/3 patients in an international, multicenter, non-inferiority study. The study began as a real-world, investigator-initiated study conducted in Germany and then the patient population was expanded to include centers in Europe and Asia-Pacific. In total, 682 patients were treated. Of these, 80.2 percent were G3 and 53.1 percent had high baseline viral load (greater than or equal to 600,000 IU/mL), both negative factors for achieving SVR.

Eligible patients were randomized to one of three arms: (A) PEGINTRON (1.5 mcg/kg/wk) for 24 weeks (approved dose), (B) PEGINTRON (1.0 mcg/kg/wk) for 24 weeks (low dose) or (C) PEGINTRON (1.5 mcg/kg/wk) for 16 weeks (short duration), each in combination with weight-based REBETOL (800-1200 mg/day). Co-primary end points were non-inferiority between arms A and B and A and C. SVR rates overall were (A) 66.5 percent (153/230), (B) 64.3 percent (144/224) and (C) 56.6 percent (129/228). Neither
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SAN FRANCISCO, Calif. , Aug. 28, 2015 /PRNewswire/ ... for the treatment of cancer, today announced the filing ... U.S. Securities and Exchange Commission (SEC) relating to a ... number of shares to be offered and the price ... CytomX intends to list its common stock under the ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Roche under the trade name of ... the world. In Feb.26, 2010, it was approved by ... available in China all come ...
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final ... (CDC) Contact Lens Health Week, 1-800 Contacts is sharing ... found that contact lens wearers who do not properly ... risk for eye infections. Most contact ... lenses, but a clean lens case is sometimes overlooked.  ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... WESTON, Fla., Jan. 14, 2011 American Scientific ... (Pink Sheets: ASFX ) wishes to announces that ... is available at www.sec.gov , has been declared effective ... Registration Statement means that the Company will commence reporting of ...
... Research Institute (IDRI) today announced it has received a ... Foundation for "Chemical genomics for the identification of targets ... is to identify new leads and new drug targets ... of producing new drugs to treat tuberculosis (TB). The ...
Cached Medicine Technology:American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements 2IDRI Awarded Grant from Bill and Melinda Gates Foundation to Identify Candidates for Novel TB Drugs 2
(Date:8/29/2015)... ... August 29, 2015 , ... "I ... from Miller Place, N.Y. "I specialize in manual therapy, and my invention will ... can be used for additional muscle dysfunction throughout the body." , They developed ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Next weekend ... of summer (which astronomically, officially ends on September 22nd this year). For IT security ... security hangovers linger on which could prove far more costly than a simple headache. ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health ... and sell Arterosil and Arterosil HP, and that all claims and counterclaims have ... Health Sciences, LLC (VHS) in the United States District Court for the Southern ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a non-invasive ... two years, the longest of any cellulite reduction system currently on the market. ... solution for their cellulite, according to Dr. Robert Weiss, director of the premier MD ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... survey of businesses that looks at their preparations for ... Health (HSPH) researchers found that only one-third believe they ... half their workforce were absent for two weeks due ... believe they could avoid such problems for one month ...
... In a new report, University of Illinois professor Barbara H. Fiese ... promote family mealtimes as a matter of public policy. "There ... protecting their families as taking 18 to 20 minutes to eat ... week," said Fiese, a U of I professor of human development ...
... WASHINGTON, Sept. 9 The Henry M. Jackson Foundation ... Tug McGraw Foundation (TMF) and Grammy Award-winning country music stars Tim ... from the Frontlines to the Homefront ." The presenting sponsor of ... Country United is a two-day event dedicated to supporting ...
... , BOSTON, Sept. 9 A recent study ... of laboratory use and confinement. Developmental Context Effects on ... the September issue, Vol. 45 (5), of the American Psychological ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090909/DC72238 ) , ...
... , , , ... the global anti-aging skincare market approached $15 billion(1), with 32 ... many over-the-counter products are claiming to achieve comparable benefits as ... to grow, but FDA-approved prescription products with rigorous efficacy and ...
... Workforce Prescriptions ("WRX") announced on Tuesday the launch of the Paradigm ... by a private endowment, developed to honor hospitals that have gone ... without resorting to workforce reductions or dramatic top-down mandates. , ... the paradigm shift in understanding required to see that the number ...
Cached Medicine News:Health News:Four-fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 2Health News:Four-fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 3Health News:Four-fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 4Health News:U of I acientist: Public policy should promote family mealtimes 2Health News:U of I acientist: Public policy should promote family mealtimes 3Health News:Tim McGraw and Faith Hill Lead Country United Effort to Benefit Military Medicine 2Health News:Tim McGraw and Faith Hill Lead Country United Effort to Benefit Military Medicine 3Health News:Chimpanzees Suffer Psychologically Like Humans 2Health News:Chimpanzees Suffer Psychologically Like Humans 3Health News:Leading Anti-Aging Prescription RENOVA(R) Continues To Deliver Maximum Results 2Health News:Leading Anti-Aging Prescription RENOVA(R) Continues To Deliver Maximum Results 3Health News:WRX Launches National Labor Efficiency Quality Award 2Health News:WRX Launches National Labor Efficiency Quality Award 3
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 130o....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
25 gauge cannula. 2 mm vertical spatula tip with opening on right side. 10 mm from tip to bend. Polished finish....
Angled blade and flat serrated handle with polished finish. Blade: 1 mm x 10 mm....
Medicine Products: